Navigation Links
Cynvenio Launches Newest LiquidBiopsy HER2 Expression Test

Cynvenio Biosystems, Inc., a leader in liquid biopsy testing technology for personalized medicine, today announced the launch of its new ClearID HER2 Expression Test. The new test allows doctors to perform real-time monitoring and analysis of HER2 levels in their patients without using tissue biopsy. Cynvenio’s test is performed from a normal blood draw and is especially suited in cases where tissue biopsy is not possible, for example after a lumpectomy or other resection of the primary tumor.

Over-expression of HER2 occurs in approximately 15–20% of breast cancers and 10–30% of gastric / gastroesophageal cancers and serves as both a prognostic and predictive biomarker. HER2 over-expression has also been observed in other malignancies including ovary, endometrium, bladder, lung, colon, and head and neck. 

“We have developed a robust methodology to isolate HER2-positive circulating tumor cells from the peripheral blood and cerebral spinal fluid of breast cancer patients with both early stage and metastatic disease,” said Paul Y. Song, MD, Cynvenio’s Chief Medical Officer. “We also isolate HER2-positive circulating tumor cells in gastric and colon cancer, and we believe this new LiquidBiopsy test provides clinicians with valuable real-time insight into disease response to HER2 targeted therapy.”

In addition to what is known about tumor heterogeneity, studies have found that HER2 status can change during tumor progression. In cases of local and systemic relapse, HER2 status has been shown to switch between positive and negative in up to 25% of patients?.

“Blood-based testing ensures the treating physician is not misled by tumor heterogeneity or changes in tumor biology over time,” said Pat Whitworth MD, Director, Nashville Breast Center. “Liquid biopsy offers a very practical way to characterize the tumor and monitor treatment effect. For cancers that become HER2 positive during treatment, this technology can detect a clinically meaningful opportunity for effective management.”

The HER2 test leverages Cynvenio’s LiquidBiopsy platform and uses antibodies against EpCAM, TROP2, HER2, and EGFR, delivering ultra-high purity outputs with >95% specificity and sensitivity. The test has a 3-7 day turn-around time and is processed by Cynvenio’s CLIA/CAP laboratory in California. It is also available to all laboratories running Cynvenio’s LiquidBiopsy platform and workflow. Clinicians or scientists interested in ordering the test kit can visit or for more information.

About Cynvenio Biosystems, Inc.

Cynvenio’s LiquidBiopsy® testing technology provides affordable and clinically actionable precision medicine strategies for physicians treating cancer patients.  The company’s core offerings include the ClearID® family of blood tests for tumor assessment and patient monitoring, and the LiquidBiopsy® platform and consumables for deployment in third party labs and hospitals. Cynvenio is based in Westlake Village, California. For more information, please visit,, and

?Lindstrom et al., J. Clin. Oncology 2012; Wallwiever et al., BMC Cancer 2015.

LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cynvenio and Saint Luke’s Cancer Institute Launch Pilot Study to Evaluate the Potential for Early Detection of Recurrent Breast Cancer Following Therapy
2. Cynvenio Announces New LiquidBiopsy Test for PD-L1 Expression in Lung Cancer
3. Cynvenio Announces New Deployment of LiquidBiopsy® System at Leading Cancer Research Center in South Korea
4. Cynvenio Announces ClearID® Commercial Distribution Agreements for Israel, Greece, Argentina and South Korea
5. Cynvenio’s LiquidBiopsy® Platform-Derived Research Data to be Presented at the 2017 ASCO Annual Meeting, June 2-June 6, 2017 in Chicago, Illinois
6. Cynvenio Research Highlights Need for Longitudinal Monitoring of Triple Negative Breast Cancer Patients
7. Cynvenio Releases ClearID® Lung Cancer: a Highly-Targeted Genomic Blood Test for Lung and Thoracic Cancer Patients
8. Cynvenio and TME Research Announce Neoadjuvant Breast Cancer Monitoring Study (NEAT)
9. Cynvenio Releases Two New High Recovery LiquidBiopsy® CTC Capture Kits at 2017 AACR Annual Meeting in Washington, DC.
10. Cynvenio Biosystems Announces Expansion of Payer Network with Addition of Blue Cross Blue Shield of Illinois
11. Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test
Post Your Comments:
(Date:3/3/2020)... ... March 03, 2020 , ... Ideal Implant Incorporated Founder and ... technology at the IMCAS Innovation Shark Tank 2020 in Paris, France in January. ... and aesthetic science industries that promise to revolutionize medical practices in their fields. ...
(Date:2/28/2020)... (PRWEB) , ... February 26, 2020 , ... ... system combines a high-speed camera with a dedicated controller, thus simplifying setup, ... per second, the HS7 is the first of Fastec Imaging’s new HS Series ...
(Date:2/21/2020)... (PRWEB) , ... February 20, 2020 , ... In a ... join guest speakers from Synteract including Lisa Dilworth, BS, MS, Vice President ... about these challenges, with feasible strategies and solutions to support patients, sites and sponsors. ...
(Date:2/21/2020)... ... February 20, 2020 , ... The dietary supplement ... consumers that what’s listed on an ingredient panel is actually in their product. ... solution with the adoption of CertainT, which is designed to protect the intellectual ...
Breaking Biology Technology:
(Date:2/28/2020)... ... ... Regen Suppliers is now offering the top FDA Cleared threads available on ... not only one of the only FDA Cleared options available, there are fifteen different ... popularity, as they represent an excellent nonoperative method of reducing wrinkles and helping individuals ...
(Date:2/28/2020)... ... February 28, 2020 , ... ... biologics orders. This includes all available stem cell and exosome biologics. , Regen ... tissue, Exosome Biologics, PRP kits, adipose kits, PDO thread lifts and more. ...
(Date:2/21/2020)... VIEW, Calif. (PRWEB) , ... February 20, 2020 ... ... sorting and dispensing platforms, announced today that it has entered into a collaboration ... single cell isolation on HepaTx’s unique hepatocyte-like cells (iHeps) developed from adipose tissue-derived ...
Breaking Biology News(10 mins):